JP6969848B2 - プリナブリン組成物 - Google Patents

プリナブリン組成物 Download PDF

Info

Publication number
JP6969848B2
JP6969848B2 JP2018501232A JP2018501232A JP6969848B2 JP 6969848 B2 JP6969848 B2 JP 6969848B2 JP 2018501232 A JP2018501232 A JP 2018501232A JP 2018501232 A JP2018501232 A JP 2018501232A JP 6969848 B2 JP6969848 B2 JP 6969848B2
Authority
JP
Japan
Prior art keywords
mixture
prinabrin
monohydrate
composition
purinabrin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018501232A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018520178A5 (enExample
JP2018520178A (ja
Inventor
ファン，ラン
シン，アニルッダ
Original Assignee
ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57757489&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6969848(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド filed Critical ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド
Publication of JP2018520178A publication Critical patent/JP2018520178A/ja
Publication of JP2018520178A5 publication Critical patent/JP2018520178A5/ja
Priority to JP2021138150A priority Critical patent/JP2021181497A/ja
Application granted granted Critical
Publication of JP6969848B2 publication Critical patent/JP6969848B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/004—Fractional crystallisation; Fractionating or rectifying columns
    • B01D9/0045—Washing of crystals, e.g. in wash columns
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/005—Selection of auxiliary, e.g. for control of crystallisation nuclei, of crystal growth, of adherence to walls; Arrangements for introduction thereof
    • B01D9/0054—Use of anti-solvent
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/0063—Control or regulation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D2009/0086—Processes or apparatus therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2018501232A 2015-07-13 2016-07-11 プリナブリン組成物 Active JP6969848B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021138150A JP2021181497A (ja) 2015-07-13 2021-08-26 プリナブリン組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562191990P 2015-07-13 2015-07-13
US62/191,990 2015-07-13
PCT/US2016/041773 WO2017011399A1 (en) 2015-07-13 2016-07-11 Plinabulin compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021138150A Division JP2021181497A (ja) 2015-07-13 2021-08-26 プリナブリン組成物

Publications (3)

Publication Number Publication Date
JP2018520178A JP2018520178A (ja) 2018-07-26
JP2018520178A5 JP2018520178A5 (enExample) 2019-08-29
JP6969848B2 true JP6969848B2 (ja) 2021-11-24

Family

ID=57757489

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018501232A Active JP6969848B2 (ja) 2015-07-13 2016-07-11 プリナブリン組成物
JP2021138150A Pending JP2021181497A (ja) 2015-07-13 2021-08-26 プリナブリン組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021138150A Pending JP2021181497A (ja) 2015-07-13 2021-08-26 プリナブリン組成物

Country Status (21)

Country Link
US (5) US10155748B2 (enExample)
EP (2) EP3334726B1 (enExample)
JP (2) JP6969848B2 (enExample)
KR (1) KR102680823B1 (enExample)
CN (3) CN109516981B (enExample)
AU (2) AU2016291708B2 (enExample)
BR (1) BR112018000229A2 (enExample)
CA (1) CA2991059C (enExample)
CL (1) CL2018000098A1 (enExample)
CO (1) CO2018000350A2 (enExample)
DK (1) DK3334726T3 (enExample)
EC (1) ECSP18010481A (enExample)
ES (1) ES2910035T3 (enExample)
IL (1) IL256559B2 (enExample)
MX (1) MX376122B (enExample)
MY (1) MY181892A (enExample)
NZ (1) NZ778077A (enExample)
PE (1) PE20180528A1 (enExample)
PH (1) PH12018500071A1 (enExample)
SG (1) SG10202108194XA (enExample)
WO (1) WO2017011399A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10238650B2 (en) 2015-03-06 2019-03-26 Beyondspring Pharmaceuticals, Inc. Method of treating cancer associated with a RAS mutation
SG11201707128TA (en) 2015-03-06 2017-09-28 Beyondspring Pharmaceuticals Inc Method of treating a brain tumor
ES2910035T3 (es) 2015-07-13 2022-05-11 Beyondspring Pharmaceuticals Inc Composiciones de plinabulina
BR112018016054A2 (pt) 2016-02-08 2019-02-12 Beyondspring Pharmaceuticals, Inc. composições farmacêuticas e/ou métodos para tratar câncer e/ou para romper vasculatura de tumor associada ao câncer em indivíduo
MX389200B (es) 2016-06-06 2025-03-20 Beyondspring Pharmaceuticals Inc Composición y método para reducir la neutropenia.
CN114276332B (zh) 2016-08-12 2023-08-18 深圳华大海洋科技有限公司 脱氢苯基阿夕斯丁类化合物的多晶型及其制备纯化方法和应用
CN107011331A (zh) * 2016-08-12 2017-08-04 青岛海洋生物医药研究院股份有限公司 脱氢苯基阿夕斯丁类化合物的多晶型及其制备方法
CN110431135A (zh) 2017-01-06 2019-11-08 大连万春布林医药有限公司 微管蛋白结合化合物及其治疗用途
KR20190109479A (ko) 2017-02-01 2019-09-25 비욘드스프링 파마수티컬스, 인코포레이티드. 호중구감소증의 감소 방법
EP3661927A1 (en) 2017-08-03 2020-06-10 Pliva Hrvatska D.O.O. Salts and solid state forms of plinabulin
WO2019147615A1 (en) 2018-01-24 2019-08-01 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing thrombocytopenia via the administration of plinabulin
JP2024513505A (ja) 2021-04-09 2024-03-25 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド 腫瘍を治療するための組成物及び方法
EP4475811A1 (en) * 2022-02-10 2024-12-18 Beyondspring Pharmaceuticals, Inc. Stable plinabulin formulations and methods of their preparation and use
CN117860672A (zh) 2022-10-11 2024-04-12 大连万春布林医药有限公司 一种普那布林胶束组合物及其制备方法

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS509164A (enExample) 1973-05-11 1975-01-30
DE3175083D1 (en) 1980-12-18 1986-09-11 Wellcome Found Pharmaceutical compounds, their preparation and use
AU576322B2 (en) 1983-07-22 1988-08-25 Ici Australia Limited Alpha-substituted-alpha-cyanomethyl alcohols
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
JPH05255106A (ja) 1990-10-31 1993-10-05 Toray Ind Inc 血小板減少症治療剤
JPH059164A (ja) 1991-07-02 1993-01-19 Sumitomo Chem Co Ltd 光学活性マンデロニトリル誘導体の製造方法
GB9217331D0 (en) 1992-08-14 1992-09-30 Xenova Ltd Pharmaceutical compounds
US5872151A (en) 1992-10-01 1999-02-16 Glaxo Wellcome Inc. Immunopotentiatory agents and physiologically acceptable salts thereof
DK0609606T3 (enExample) 1992-10-01 1997-03-17 Wellcome Found
US6096786A (en) 1992-10-01 2000-08-01 Glaxo Wellcome Inc. Immunopotentiatory agent and physiologically acceptable salts thereof
JP2880292B2 (ja) 1992-11-27 1999-04-05 ナプロ バイオセラピューティクス，インコーポレイテッド 注射可能組成物
JPH0725858A (ja) 1993-07-13 1995-01-27 Otsuka Pharmaceut Co Ltd ピペラジン誘導体
US5958980A (en) 1993-08-26 1999-09-28 Glaxo Wellcome, Inc. Immunopotentiatory agent and physiologically acceptable salts thereof
IL110787A0 (en) 1993-08-27 1994-11-11 Sandoz Ag Biodegradable polymer, its preparation and pharmaceutical composition containing it
GB9402809D0 (en) 1994-02-14 1994-04-06 Xenova Ltd Pharmaceutical compounds
GB9402807D0 (en) 1994-02-14 1994-04-06 Xenova Ltd Pharmaceutical compounds
GB9426224D0 (en) 1994-12-23 1995-02-22 Xenova Ltd Pharmaceutical compounds
US5891877A (en) 1995-02-14 1999-04-06 Xenova Limited Pharmaceutical compounds
US5874443A (en) 1995-10-19 1999-02-23 Trega Biosciences, Inc. Isoquinoline derivatives and isoquinoline combinatorial libraries
US5886210A (en) 1996-08-22 1999-03-23 Rohm And Haas Company Method for preparing aromatic compounds
JP3131574B2 (ja) 1996-09-04 2001-02-05 新日本製鐵株式会社 新規抗腫瘍物質、該物質を製造するための微生物及び方法、並びに該物質を有効成分とする細胞周期阻害剤及び抗腫瘍剤
US5939098A (en) 1996-09-19 1999-08-17 Schering Corporation Cancer treatment with temozolomide
US5922683A (en) 1997-05-29 1999-07-13 Abbott Laboratories Multicyclic erythromycin derivatives
AU749214C (en) 1997-11-21 2006-03-30 Purdue Neuroscience Company Substituted 2-aminoacetamides and the use thereof
HUP0101329A3 (en) 1998-01-29 2002-07-29 Aventis Pharmaceuticals Inc Co Method for preparing an n-[(aliphatic or aromatic)carbonyl]-2-aminoacetamide compounds and a cyclyzed compounds there from
US7141603B2 (en) 1999-02-19 2006-11-28 The Regents Of The University California Antitumor agents
US6069146A (en) 1998-03-25 2000-05-30 The Regents Of The University Of California Halimide, a cytotoxic marine natural product, and derivatives thereof
HUP0103460A3 (en) 1998-03-26 2002-11-28 Shionogi & Co Indole derivatives with antiviral activity and pharmaceutical compositions containing them
US6509331B1 (en) 1998-06-22 2003-01-21 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
FR2784988B1 (fr) 1998-10-23 2002-09-20 Adir Nouveaux composes dihydro et tetrahydroquinoleiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6358957B1 (en) 1998-11-12 2002-03-19 Nereus Pharmaceuticals, Inc. Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds
US7026322B2 (en) 1998-11-12 2006-04-11 Nereus Pharmaceuticals, Inc. Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds
DK1210428T3 (en) 1999-08-23 2015-06-15 Dana Farber Cancer Inst Inc PD-1, a receptor for B7-4 AND USE THEREOF
BR0013542A (pt) 1999-08-23 2002-05-14 Dana Farber Cancer Inst Inc Moléculas b7-4 e usos para as mesmas
EP3225632B1 (en) 1999-11-30 2020-05-06 Mayo Foundation for Medical Education and Research Antibodies binding to b7-h1, a novel immunoregulatory molecule
AU782917C (en) 2000-01-18 2006-11-23 Beyondspring Pharmaceuticals, Inc. Cell division inhibitors and process for producing the same
US6649172B2 (en) 2000-03-17 2003-11-18 Corixa Corporation Amphipathic aldehydes and their uses as adjuvants and immunoeffectors
JP5101781B2 (ja) 2000-05-09 2012-12-19 アンギオアールエックス コーポレイション ピペラジンジオン化合物
WO2002064592A1 (en) 2000-12-28 2002-08-22 Neurocrine Biosciences, Inc. Tricyclic crf receptor antagonists
US20030082140A1 (en) 2001-08-20 2003-05-01 Fisher Paul B. Combinatorial methods for inducing cancer cell death
AU2003213673A1 (en) 2002-03-01 2003-09-16 Pintex Pharmaceuticals, Inc. Pin1-modulating compounds and methods of use thereof
CA2486124A1 (en) 2002-05-17 2003-11-27 Aventis Pharma S.A. Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer
US7012100B1 (en) 2002-06-04 2006-03-14 Avolix Pharmaceuticals, Inc. Cell migration inhibiting compositions and methods and compositions for treating cancer
AU2003302721B2 (en) * 2002-08-02 2009-10-08 Beyondspring Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
US7935704B2 (en) 2003-08-01 2011-05-03 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
CN101633655B (zh) * 2002-08-02 2014-04-30 大连万春药业有限公司 脱氢苯基阿夕斯丁及其类似物以及脱氢苯基阿夕斯丁及其类似物的合成
US7919497B2 (en) 2002-08-02 2011-04-05 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
BR0316880A (pt) 2002-12-23 2005-10-25 Wyeth Corp Anticorpos contra pd-1 e usos dos mesmos
US20040197312A1 (en) 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
BRPI0506655A (pt) * 2004-02-04 2007-05-08 Nereus Pharmaceuticals Inc dehidrofenilahistinas e seus análogos, e sìntese de dehidrofenilahistinas e seus análogos
CN1934101B (zh) * 2004-02-04 2011-10-12 尼瑞斯药品公司 脱氢苯基阿夕斯丁及其类似物以及脱氢苯基阿夕斯丁及其类似物的合成
ES2577303T3 (es) 2004-04-19 2016-07-14 Krka, Tovarna Zdravil, D.D., Novo Mesto Procedimientos para la preparación de la forma polimórfica I de hidrogenosulfato de clopidogrel
DE202004018940U1 (de) 2004-12-07 2006-04-13 Asf Verwaltungs Gmbh Druckverschluß, Druckverschlußband und wiederverschließbarer Beutel
JP4559240B2 (ja) 2005-01-13 2010-10-06 株式会社エヌ・ティ・ティ・ドコモ 移動通信システム、無線基地局、無線回線制御局及び電力制御方法
CA2970873C (en) 2005-05-09 2022-05-17 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
EA019344B1 (ru) 2005-07-01 2014-03-31 МЕДАРЕКС, Эл.Эл.Си. Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения
WO2007035841A1 (en) 2005-09-21 2007-03-29 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
US20090130098A1 (en) 2006-01-18 2009-05-21 Merck Patent Gmbh Specific therapy using integrin ligands for treating cancer
CA2647282A1 (en) 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
US8129527B2 (en) * 2006-11-03 2012-03-06 Nereus Pharmacuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
CA2678353A1 (en) 2007-02-15 2008-08-21 Mannkind Corporation A method for enhancing t cell response
US20080255035A1 (en) 2007-04-13 2008-10-16 Abraxis Bioscience, Inc. Sparc and methods of use thereof
US20090170837A1 (en) 2007-08-17 2009-07-02 Thallion Pharmaceuticals Inc. Methods for treating ras driven cancer in a subject
US8569262B2 (en) 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
EP2227296B1 (en) 2008-01-08 2015-11-25 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with tubulin modulating agents for the treatment of proliferative diseases
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
UY31952A (es) 2008-07-02 2010-01-29 Astrazeneca Ab 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim
FI4209510T3 (fi) 2008-12-09 2024-03-22 Hoffmann La Roche Anti-PD-L1-vasta-aineita ja niiden käyttö T-solutoiminnan tehostamiseksi
CN102378635A (zh) 2009-01-16 2012-03-14 特瓦制药工业有限公司 重组人白蛋白-人粒细胞集落刺激因子融合蛋白的新稳定制剂
WO2010114922A1 (en) 2009-03-31 2010-10-07 Agios Pharmaceuticals, Inc. Methods of treating cancer having an aberrant egfr or kras genotype
GB0907551D0 (en) 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
DK2464218T3 (en) 2009-08-10 2015-07-20 Univ Texas Treatment of brain metastases with inhibitors of endothelin receptors in combination with a cytotoxic agent for chemotherapy
EP2477985B1 (en) 2009-09-15 2018-11-07 BlueLink Pharmaceuticals, Inc. Crlx101 for use in the treatment of cancer
MX2012004721A (es) 2009-10-23 2012-06-25 Mannkind Corp Inmunoterapia de cancer y metodo de tratamiento.
LT3279215T (lt) 2009-11-24 2020-04-10 Medimmune Limited Tiksliniai surišantys agentai prieš b7-h1
CN101766815B (zh) 2009-12-31 2012-04-25 胡松华 紫杉醇及多西紫杉醇的用途
WO2011109625A1 (en) 2010-03-03 2011-09-09 Targeted Molecular Diagnostics, Llc Methods for determining responsiveness to a drug based upon determination of ras mutation and/or ras amplification
EP2571577A1 (en) 2010-05-17 2013-03-27 Bristol-Myers Squibb Company Improved immunotherapeutic dosing regimens and combinations thereof
US20130131018A1 (en) 2010-06-04 2013-05-23 Exonhit S.A. Substituted isoquinolines and their use as tubulin polymerization inhibitors
JP2012033526A (ja) 2010-07-28 2012-02-16 Fuji Electric Co Ltd 薄膜太陽電池およびその製造方法
WO2012035436A1 (en) * 2010-09-15 2012-03-22 Tokyo University Of Pharmacy And Life Sciences Plinabulin prodrug analogs and therapeutic uses thereof
EP2646577A2 (en) 2010-11-29 2013-10-09 Precision Therapeutics Inc. Methods and systems for evaluating the sensitivity or resistance of tumor specimens to chemotherapeutic agents
TWI386203B (zh) 2011-01-07 2013-02-21 Univ China Medical 治療腦癌或用以降低腦癌細胞對替莫唑胺之抗藥性之醫藥組合物及其應用
RS57324B1 (sr) 2011-04-20 2018-08-31 Medimmune Llc Antitela i drugi molekuli koji vezuju b7-h1 i pd-1
JP2014533955A (ja) 2011-11-28 2014-12-18 ナショナル リサーチ カウンシル オブ カナダ パクリタキセル応答性がんマーカー
US20150004175A1 (en) 2011-12-13 2015-01-01 Yale University Compositions and Methods for Reducing CTL Exhaustion
MX384023B (es) 2012-05-09 2025-03-14 Cantex Pharmaceuticals Inc Tratamiento de mielosupresion.
AU2013204313C1 (en) 2012-06-01 2016-04-07 Bionomics Limited Combination Therapy
CA2889182A1 (en) 2012-10-26 2014-05-01 The University Of Chicago Synergistic combination of immunologic inhibitors for the treatment of cancer
EP2958943B1 (en) 2013-02-20 2019-09-11 The Trustees Of The University Of Pennsylvania Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
AU2014244083B2 (en) 2013-03-13 2018-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for modulating chemotherapeutic cytotoxicity
WO2014174480A1 (en) 2013-04-24 2014-10-30 Tel Hashomer Medical Research Infrastructure And Services Ltd. Magnetic resonance maps for analyzing tissue
BR112015028326A8 (pt) 2013-06-03 2018-01-23 Novartis Ag combinações de anticorpo anti-pd-l1, inibidor de mek e/ou inibidor de braf, seus kits e seus usos, e composição farmacêutica
EP3076972B1 (en) 2013-10-11 2021-10-06 BeyondSpring, Inc. Cancer treatment with combination of plinabulin and taxane
EP3065772B1 (en) 2013-11-05 2024-07-24 Cognate Bioservices, Inc. Combinations of checkpoint inhibitors and therapeutics to treat cancer
WO2015069790A1 (en) 2013-11-06 2015-05-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method for subtyping lymphoma types by means expression profiling
CN104796448B (zh) 2014-01-22 2019-02-12 腾讯科技（深圳）有限公司 网络系统的数据处理方法和装置
US9850225B2 (en) 2014-04-14 2017-12-26 Bristol-Myers Squibb Company Compounds useful as immunomodulators
CN106794246B (zh) 2014-08-08 2021-10-15 OncoQuest制药有限公司 肿瘤抗原特异性抗体和tlr3刺激以增强检查点干扰癌症疗法的性能
US20180028531A1 (en) 2015-02-12 2018-02-01 BeyondSpring Phamaceuticals, Inc. Use of plinabulin in combination with immune checkpoint inhibitors
SG11201707128TA (en) 2015-03-06 2017-09-28 Beyondspring Pharmaceuticals Inc Method of treating a brain tumor
US10238650B2 (en) 2015-03-06 2019-03-26 Beyondspring Pharmaceuticals, Inc. Method of treating cancer associated with a RAS mutation
WO2016165007A1 (en) 2015-04-17 2016-10-20 The University Of British Columbia Inhibitors of estrogen receptor alpha and their use as therapeutics for cancer
ES2910035T3 (es) 2015-07-13 2022-05-11 Beyondspring Pharmaceuticals Inc Composiciones de plinabulina
EP3359692A4 (en) 2015-10-05 2019-05-01 Cedars-Sinai Medical Center METHOD FOR CLASSIFYING AND TREATING CANCER
BR112018016054A2 (pt) 2016-02-08 2019-02-12 Beyondspring Pharmaceuticals, Inc. composições farmacêuticas e/ou métodos para tratar câncer e/ou para romper vasculatura de tumor associada ao câncer em indivíduo
MX389200B (es) 2016-06-06 2025-03-20 Beyondspring Pharmaceuticals Inc Composición y método para reducir la neutropenia.
CN110431135A (zh) 2017-01-06 2019-11-08 大连万春布林医药有限公司 微管蛋白结合化合物及其治疗用途
KR20190109479A (ko) 2017-02-01 2019-09-25 비욘드스프링 파마수티컬스, 인코포레이티드. 호중구감소증의 감소 방법
EP3595653B1 (en) 2017-03-13 2023-03-08 Beyondspring Pharmaceuticals, Inc. Compositions of plinabulin and use thereof
WO2019147615A1 (en) 2018-01-24 2019-08-01 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing thrombocytopenia via the administration of plinabulin
KR20200116477A (ko) 2018-02-01 2020-10-12 비욘드스프링 파마수티컬스, 인코포레이티드. 플리나불린 및 g-csf 제제의 투여를 통해 화학요법-유도된 호중구감소증을 감소시키기 위한 조성물 및 방법
MX420412B (es) 2018-06-01 2025-02-10 Beyondspring Pharmaceuticals Inc Plinabulina, composiciones que la comprenden y sus usos en el tratamiento de cáncer asociado con mutación del egfr.
JP2021534183A (ja) 2018-08-16 2021-12-09 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド 免疫応答を刺激するための方法及び組成物

Also Published As

Publication number Publication date
KR20180027563A (ko) 2018-03-14
PE20180528A1 (es) 2018-03-19
IL256559B2 (en) 2023-07-01
CN113735834A (zh) 2021-12-03
CN109516981B (zh) 2019-10-22
EP3334726A4 (en) 2019-04-17
US20200277280A1 (en) 2020-09-03
SG10202108194XA (en) 2021-09-29
CN109516981A (zh) 2019-03-26
CA2991059C (en) 2024-01-16
US20190106410A1 (en) 2019-04-11
KR102680823B1 (ko) 2024-07-03
US20220169635A1 (en) 2022-06-02
CO2018000350A2 (es) 2018-06-12
US20180194749A1 (en) 2018-07-12
CN113735834B (zh) 2023-06-13
PH12018500071B1 (en) 2018-07-23
BR112018000229A2 (pt) 2018-09-04
IL256559A (en) 2018-02-28
PH12018500071A1 (en) 2018-07-23
MX2018000451A (es) 2018-05-07
ES2910035T3 (es) 2022-05-11
EP4011878A1 (en) 2022-06-15
NZ739083A (en) 2024-11-29
US10155748B2 (en) 2018-12-18
DK3334726T3 (da) 2022-05-16
HK1251559A1 (zh) 2019-02-01
AU2021201784B2 (en) 2022-12-01
CA2991059A1 (en) 2017-01-19
US20240425485A1 (en) 2024-12-26
AU2016291708B2 (en) 2020-12-24
CL2018000098A1 (es) 2018-07-20
CN108026075A (zh) 2018-05-11
AU2021201784A1 (en) 2021-04-15
MX376122B (es) 2025-03-07
JP2018520178A (ja) 2018-07-26
US11254657B2 (en) 2022-02-22
WO2017011399A1 (en) 2017-01-19
US12024501B2 (en) 2024-07-02
MY181892A (en) 2021-01-12
NZ778077A (en) 2024-11-29
US10550104B2 (en) 2020-02-04
ECSP18010481A (es) 2018-04-30
IL256559B1 (en) 2023-03-01
CN108026075B (zh) 2021-06-29
EP3334726B1 (en) 2022-03-16
EP3334726A1 (en) 2018-06-20
JP2021181497A (ja) 2021-11-25
AU2016291708A1 (en) 2018-02-01

Similar Documents

Publication Publication Date Title
JP6969848B2 (ja) プリナブリン組成物
AU2022259767B2 (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
US20120035142A1 (en) Polymorphs of darunavir
KR102903080B1 (ko) 약제학적 화합물, 이의 염, 이의 제형, 그리고 이의 제조 방법 및 사용 방법
JP2019089822A (ja) トピロキソスタットの新規結晶形及びその製造方法
RU2773843C1 (ru) Композиции плинабулина
HK40006402A (en) Plinabulin compositions
HK40006402B (en) Plinabulin compositions
HK1251559B (zh) 普那布林组合物
KR20260007293A (ko) 약제학적 화합물, 이의 염, 이의 제형, 그리고 이의 제조 방법 및 사용 방법
NZ719970B2 (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190709

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190709

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200528

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200616

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200916

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201116

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210427

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210826

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210826

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20210903

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20210907

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210928

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211026

R150 Certificate of patent or registration of utility model

Ref document number: 6969848

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250